Christine Johnston warns a thin biosimilar pipeline keeps specialty costs high and slows innovation and urges payers to check their PBM’s top 25 drugs.
|Articles|October 1, 2003
Resource Returns
Author(s)Tracey Walker
On the surfacE, ordering surgical gloves would seem to be a rather simple task for any hospital. But what happens when five or 10 hospitals merge and each facility has its own favorite type of glove, and each type of glove comes from a different vendor?
Advertisement
Advertisement
Related to this article
Speakers and researchers at this year's meeting in San Diego focused on drug pricing policy, getting savings to patients at the pharmacy counter and keeping people in charge of AI.
The generic twice-yearly HIV prevention shot is expected to cost $40 a year in 120 countries, 16 months after Gilead's original approval.
Annual healthcare costs jump by almost $25,000 with targeted therapy for atopic dermatitis that avoided costs from reduced hospitalizations and ER visits only partly offset, according to recently reported research findings.
Findings from an analysis of IQVIA claims data show a prevalence rate that is five times lower than previous reports. Some of the discrepancy could be chalked up to the difference between using claims data instead of self-reporting by survey respondents.
In the MDT-BRIDGE trial, 92% of patients with stage II-III lung cancer reached surgery or chemoradiation after a midtreatment tumor board review.
Epic Research finds over half of children with type 1 diabetes miss autoantibody testing, risking misdiagnosis and limiting early treatment options like Tzield.
Higher MRI-measured liver disease activity was linked to lower quality of life and more anxiety and activity problems in 802 adults with suspected MASLD/MASH in Europe.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Bronchiectasis 101: Why permanently dilated airways drive recurrent exacerbations
2
FDA tentatively approves first generic lenacapavir for HIV prevention in lower-income countries
3
From MFP fallout to AI guardrails: What stood out at AMCP Nexus 2026
4
Christine Johnston on the biosimilar pipeline and PBM formularies
5